News

Biogen Submits BLA for Aducanumab in Alzheimer\'s Disease

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer's disease.

Genexine – GX-19

Candidate: GX-19 Category: VAX Type: DNA vaccine Status: Genexine said June 11 that it won approval from South Korea’s Ministry of Food…

Big Pharma joins forces on $1B fund to shore up struggling antibiotics makers

Big Pharma joins forces on $1B fund to shore up struggling antibiotics makers

NICE backing for Takeda's Adcetris for rare lymphoma

Standard of care in untreated systemic anaplastic large cell lymphoma (sALCL) has not changed in several decades

APEIRON, MaxCyte Enter Licensing Agreement for APN401

Will use MaxCyte’s ExPERT platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming trials.

Hepion Pharmaceuticals – CRV431

Candidate: CRV431 Type: Cyclophilin inhibitor designed to block the participation of cyclophilins in disease processes such as cell death,…

Oxford researchers develop portable COVID-19 test costing less than $25

Oxford researchers develop portable COVID-19 test costing less than $25

CMA levies fines of £2.3m in pharma probe

The fines are in addition to £8 million secured for the NHS last year as part of the case

LGC Acquires The Native Antigen Company

NAC was one of the first companies globally to offer antigens for SARS-COV-2 and continues to support the global response to the COVID-19 pandemic.

Genexine and NeoImmuneTech (NIT) – GX-I7 [also called NT-17 or Hyleukin-7™ (rhIL-7-hyFc)]

Candidate: GX-I7, also known as NT-17 or Hyleukin-7™ (rhIL-7-hyFc) Type: Homeostatic T cell growth factor composed of a covalently…

Bayer's heart failure pill hinders kidney disease, heart disease in phase 3

Bayer's heart failure pill hinders kidney disease, heart disease in phase 3

US rejects MSD/Eisai's Keytruda Lenvima combo

Regulators rejected accelerated approval as Roche's combination for the same patient population made it over the line first

Kymera, Sanofi Enter Multi-program Strategic Alliance

To develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.

Altimmune and University of Alabama at Birmingham (UAB) – NasoShield

Candidate: NasoShield Category: VAX Type: Single dose intranasal anthrax vaccine candidate Status: Altimmune said June 30 the first…

NIAID creates new COVID-19 drug and vaccine trial network through Trump's Warp Speed program

NIAID creates new COVID-19 drug and vaccine trial network through Trump's Warp Speed program

UK researchers back use of steroid inhalers during pandemic

The benefit outweighs the risks for asthma and COPD patients during the pandemic, they say

Akcea Therapeutics Appoints CMO

William Andrews will lead medical, clinical and regulatory functions in support of the company's two commercial-stage products.

Avantor Expands Life Sciences Innovation Center

The Avantor expansion in Bridgewater, NJ will address bioprocessing needs in protein science, monoclonal antibodies, cell and gene…

Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera

Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera

Gilead begins PhI trial of inhaled remdesivir

The inhaled formulation is being assessed for COVID-19 patients in the outpatient setting

Orchard Therapeutics, MolMed Extend Gene Therapy Mfg. Pact

MolMed to support the development and manufacture of vectors and drug products for Orchard’s investigational hematopoietic stem cell (HSC) gene…

Molecular Regulator Controls Abnormal Heart Growth

Scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) have cast a fresh light on a key molecular regulator in the…

Forbion moves into late-stage investing with $210M fund

Forbion moves into late-stage investing with $210M fund

Final data on ViiV's cabotegravir show impressive HIV PrEP

The long-acting, injectable therapy was 66% more effective than daily oral tablets at preventing HIV

Tris Pharma, KYE Pharmaceuticals Enter ADHD Product Alliance

KYE gains exclusive rights to commercialize Tris' FDA-approved ADHD product portfolio in Canada.

Uncover the True Identity of Your Particles with Comprehensive Particle Investigation

In this GEN webinar, Sponsored by Lonza, we will discuss examples of two types of visible particle identification and the root…

Preventing breast cancer metastasis by reactivating natural killer immune cells

Preventing breast cancer metastasis by reactivating natural killer immune cells

New clinical trial platform launched to accelerate COVID-19 treatments

AGILE is a 'proof of confidence engine' designed to quickly identify the most promising compounds for treatment of COVID-19

AGC Biologics, Molecular Partners to Develop DARPin Anti-COVID-19 Program

AGC Biologics will manufacture MP0420 at 100 liter and 1,000 liter scales for development and initial global supply.

Single-Cell RNA-Seq Reveals Progenitor Glioblastoma Stem Cell

For the first time, researchers detected what they describe as a progenitor glioblastoma stem cell (GSC). The study, the largest ever…

Takeda teams up with Twist Bioscience to boost biologics R&D

Takeda teams up with Twist Bioscience to boost biologics R&D

GSK links with Medicago to develop novel COVID-19 vaccine

Phase I clinical testing scheduled to begin mid-July

CNS Pharmaceuticals Completes API Shipments to Manufacturers

Supplies active ingredients for the production of Berubicin.

Interbacterial Toxin Leads Scientists to CRISPR-Free Method for Precise Mitochondrial Gene Editing

A team of collaborating Howard Hughes Medical Institute (HHMI) scientists has developed what they suggest is the first precision gene…

Tranquis debuts with $30M for immune cell approach to neurodegenerative diseases

Tranquis debuts with $30M for immune cell approach to neurodegenerative diseases

EU nod for Lynparza in pancreatic cancer

The drug is the only PARP inhibitor approved in this disease

Ology Bioservices Wins Department of Defense Awards

Receives three biomanufacturing contracts with a combined value of more than $16 million.

Researchers Discover How the Brain Filters out Distractions

The neural mechanisms that enable us to respond to target stimuli while ignoring distractor stimuli are poorly understood. Now researchers…

Can Biogen rebound in ALS? Maybe so, new antisense drug data suggest

Can Biogen rebound in ALS? Maybe so, new antisense drug data suggest

Regeneron kicks off Phase III trial of COVID-19 antibody cocktail

This follows a positive review from the Independent Data Monitoring Committee of REGN-COV2 Phase I safety results




Contact Us